Advancing the Future of Wellness

Discover the latest in health and longevity on "Chrysea Insights". Dive into our pioneering research and innovations in precision nutrition that are setting new standards for a healthy lifespan.

News of Chrysea

Stay informed with the latest updates and breakthroughs from Chrysea. Explore our recent discoveries, news, milestones, and the impact we're making in the world of wellness and healthy nutrition.

Press Release

Biosynthetic Blood Breakthrough: Chrysea and KaloCyte Enter  into Exclusive Alliance to Transform Medical Emergency Care.

Cantanhede, Portugal, Baltimore, USA and Dublin, Ireland; 30th September 2025 Chrysea a leading synthetic biology company focused on advancing breakthrough bioprocesses for health and longevity, today announced that it has entered into an exclusive licensing agreement with KaloCyte, Inc., a U.S. based biotechnology company developing innovative blood substitute solutions.   Under this landmark deal, Chrysea […]

Press Release

Chrysea presents additional study results on Spermidine Dietary Intake, BMI and Obesity at Benjamin Frankin Lafayette Seminar (BFLS), and significant association with reduced Cardiovascular risk markers at Gordon Research Conference (GRC)

Cantanhede, Portugal and Dublin, Ireland; 18 April 2025 In 2024, Chrysea launched Sprevive® – a pure Spermidine formulation — the first in its pipeline of clean and sustainably produced as natural products, developed using a patented precision fermentation process and supported by extensive preclinical and clinical safety data. Extensive scientific research has long established the […]

Press Release

Chrysea Unveils Groundbreaking Findings on Spermidine Dietary Intake and Cardiovascular Health at American Physiological Society (APS) Summit.

Cantanhede, Portugal and Dublin, Ireland; 10 April 2025 In 2024, Chrysea launched Sprevive® – a pure Spermidine formulation — the first in its pipeline of clean and sustainably produced natural products, developed using a patented precision fermentation process and supported by extensive preclinical and clinical safety data. Extensive scientific research has long established the critical […]

Press Release

Chrysea announces results of a double-blind randomized controlled human trial with Sprevive®.

Cantanhede, Portugal and Dublin, Ireland; 30 September 2024 A Chrysea sponsored randomized clinical study published in Nutrition Research is the first publication of a human study of high-purity (98%) spermidine. The study (NCT05459961) “Supplementation of Spermidine at 40 mg/day has Minimal Effects on Circulating Polyamines: An Exploratory Double-blind Randomized Controlled Trial in Older Men“  showed […]

Press Release

Chrysea Announces the Launch of Sprevive®: A Breakthrough in the Longevity Biotech Interventions Field.

Cantanhede, Portugal and Dublin, Ireland; 18 June 2024 Chrysea is proud to announce the launch of Sprevive®, the first of its pipeline of natural products sustainably produced using a patented precision fermentation process.   Sprevive® is pure Spermidine, a bioactive naturally found in our diet, and now for the first time sustainably produced through precision […]

Press Release

Chrysea Acquires Rodon Biologics to Strengthen Capabilities in Synthetic Biology and Biopharmaceuticals Development

Acquisition of Rodon Biologics brings operational R&D capability, skilled talent, know-how, drives capital-efficiency, synthetic biology synergy in biopharma. DUBLIN, IRELAND, February 13, 2024 /EINPresswire.com/ — Chrysea Limited (“Chrysea”), has announced the acquisition of Rodon Biologics (“Rodon”) from Iberfar Group. Rodon is a company with over 20 years of expertise in biomanufacturing and development of biological products. […]

Press Release

Chrysea and Chalmers University Partner for Development of Benzylisoquinoline Alkaloids for Use in Human and Animal Healthcare

Researchers at Chalmers University of technology have developed an innovative yeast-based platform for producing Benzylisoquinoline alkaloids (BIAs) using synthetic biology techniques. Complex stereochemistry renders chemical synthesis of BIAs largely unfeasible. Synthetic biology and sophisticated microbial engineering coupled with recent advances in the elucidation of plant BIA metabolic networks has enabled the production of high-value BIAs by precision […]

Press Release

Chrysea is shortlisted by the the prestigious Vitafoods organisation as one of 5 Most Innovative Service or Technology Providers, Supporting the Nutraceutical Industry

Chrysea has been recognised as player of excellence having successfuly integrated the complete value-chain right from the laboratory to consumer and thus being able to provide novel precision ingredients to be used accross a variety of fields, ranging from precision nutraceuticals to products with biopharmaceutical applications. The BCG group estimates that synthetic biology manufacturing could […]

Press Release

Juvenescence joins Banco Português de Fomento and 200M Fund in co-investment in Chrysea Laboratories

Juvenescence Limited (“Juvenescence”), through its JuvLife Division, joins the 200M Fund portfolio, managed by Banco Português de Fomento, in the Venture Round investment in Chrysea Labs (“Chrysea”), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms. Juvenescence and Chrysea will collaborate to develop and commercialise one of […]

Press Release

Chrysea obtains unique intellectual property portfolio on the production of polyamines which have a key role in the autophagy induction process and potentially on successful ageing in mammals

Chrysea Limited, was incorporated with the purpose to develop healthy-lifespan nutritional and supplementation interventions supported by rigorous clinical research, aimed at maintaining naturally occurring anti-ageing mechanisms such as autophagy. The company’s main technology is based on world-class synthetic biology capabilities spun-out of Professor Jens Nielsen’s labs at both the Technical University of Denmark (DTU) and […]